Serum Sclerostin Levels in Adults With Osteogenesis Imperfecta: Comparison With Normal Individuals and Response to Teriparatide Therapy

What Was Tested

The paper reports a study of Teriparatide, published as a randomized controlled trial.

Sclerostin (SOST), a glycoprotein primarily derived from osteocytes, is an important regulator of bone remodeling.

Osteogenesis imperfecta (OI) is a heritable disorder of bone characterized by low bone mass, bone fragility, recurrent fractures, and bone deformities.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

The researchers measured serum SOST levels in adults with OI who were enrolled in a randomized, placebo-controlled clinical trial that evaluated the effects of osteoanabolic therapy with teriparatide.

How the Study Was Run

The design is described as randomized and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Teriparatide and who got the comparison, which limits bias.

The comparison arm used a placebo, so changes seen with Teriparatide could be set against what happens without it.

What Was Measured

Altered SOST-mediated signaling may have a role in pathogenesis of type I collagen-related OI; however, this has not been evaluated in humans.

PubMed files the paper under topics including Adaptor Proteins, Signal Transducing, Bone Density, Bone Morphogenetic Proteins, Cancellous Bone, Case-Control Studies, Genetic Markers and Osteogenesis Imperfecta.

The authors tagged it with the keywords SCLEROSTIN (SOST) and TERIPARATIDE.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Teriparatide.

The publication is from 2018 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.

More context: the Teriparatide compound page, all human trials.